Biomerics Expands Operations in Costa Rica and Breaks Ground On a 110,000 sq. ft. New Facility

February 15, 2021

Biomerics announced it is doubling its manufacturing footprint in the La Zeta Free Trade Zone in Cartago, Costa Rica.

The company held a joint groundbreaking ceremony with La Zeta and CINDE on Friday, February 12, 2021. (Biomerics is a mid-market medical device contract manufacturer).

The expansion is via a new greenfield plant adjacent to Biomerics current operations and includes extrusion, injection molding, micro metal processing, and cleanroom assembly process. The new facility construction totaling 110,000 sq. ft. will reflect Biomerics vertically integrated, full-service business model and will include engineering labs, quality inspection labs, controlled environment manufacturing, office space, class 7 clean rooms, packaging, and warehouse facilities.

Biomerics currently employs 175 people at its 50,000 sq. ft. facility focused on extrusion, laser processing, high volume assembly, and packaging. The expansion is in support of active transfer programs with strategic customers and is expected to double its number of Costa Rican employees over the next three years.

Biomerics, Travis Sessions
Biomerics, Travis Sessions

“This expansion is in line with our vision to be the leading interventional contract manufacturer,” stated Travis Sessions, company. CEO. “Customers have requested that we build a vertically integrated operation in Costa Rica to provide cost-effective high volume manufacturing for the interventional market.”

“We are excited for the value that this expansion brings to our existing customer base in Costa Rica and interventional OEM partners around the globe,” stated Chris Richardson, Biomerics Director of Sales and Marketing. “The thriving medical device ecosystem in Costa Rica aligns well with Biomerics’ culture and innovative core.”

Construction is expected to be completed by Q4 2021 and will be celebrated with an open house.

SourceBiomerics

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”